Skip to main content

Table 1 Association between miR-7 expression and clinicopathologic characteristics

From: MiR-7 inhibits progression of hepatocarcinoma by targeting KLF-4 and promises a novel diagnostic biomarker

Features

n (%)

High expression (%)

Low expression (%)

P2 value

Gender

   

0.879/0.023

 Male

27 (77.6)

13 (67.8)

14 (32.2)

 

 Female

23 (22.4)

10 (45.7)

13 (54.3)

 

Age (year)

   

0.653/0.365

 ≥60

23 (62.2)

14 (60.8)

9 (39.2)

 

 <60

27 (37.8)

13 (55.9)

14 (44.1)

 

Tumor size (mm)

   

0.012/10.054

 ≥50

28 (71.8)

8 (71.4)

20 (28.6)

 

 <50

22 (28.2)

14 (81.8)

8 (18.2)

 

AFP (ng/mL)

   

0.275/1.256

 >400

23 (49.4)

9 (45.5)

14 (54.5)

 

 <400

27 (50.6)

13 (40.5)

14 (59.5)

 

TNM stage

   

0.027/12.864

 T1

16 (35.9)

11 (39.3)

5 (60.7)

 

 T2/T3

34 (64.1)

16 (46.0)

18 (54.0)

 

Intrahepatic metastasis status

   

0.019/1.358

 Positive

15 (30.0)

12 (80.0)

3 (20.0)

 

 Negative

35 (70.0)

18 (51.4)

17 (48.6)

 

Tumor number

 Single

32 (64.0)

14 (43.8)

18 (56.2)

0.504/9.281

 Two or more

18 (36.0)

8 (44.4)

10 (55.6)

 
  1. The statistical significance of the individuals was determined with χ2 test. P < 0.05 was considered significant